Identification of phenothiazine as an ETV1-targeting agent in gastrointestinal stromal tumors using the Connectivity Map

CHUEH-CHUAN YEN1,2, LI-TZONG CHEN3, CHIEN-FENG LI4, SAN-CHI CHEN1,2, WEI-YANG CHUA1, YUNG-CHAN LIN1, CHIAO-HAN YEN1, YEN-CHUN CHEN1, MUH-HWA YANG1,2, YEE CHAO1,2 and JONATHAN A. FLETCHER5

1Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei 11217; 2National Yang-Ming University School of Medicine, Taipei 11221; 3National Institute of Cancer Research, National Health Research Institutes, Tainan 70456; 4Department of Pathology, Chi-Mei Medical Center, Tainan 71004, Taiwan, R.O.C.; 5Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA

Received November 1, 2018; Accepted June 12, 2019

DOI: 10.3892/ijo.2019.4829

Abstract. Gastrointestinal stromal tumors (GISTs) are gastrointestinal tract sarcomas that commonly contain a mutation in the kinase genes, KIT and platelet-derived growth factor receptor A (PDGFRα). Imatinib, sunitinib and regorafenib are all effective tyrosine kinase inhibitors; however, acquired resistance is inevitable. The E26 variant 1 (ETV1) pathway has been found to be a key downstream effector of KIT and is therefore a reasonable therapeutic target for this disease. In this study, we explored the potential agents targeting ETV1 in GISTs by uploading an ETV1 knockout gene signature of GIST cell lines to the pattern-matching software ‘Connectivity Map’. The activity and mechanisms of identified agents were examined using an in vitro model. Four drugs were identified: Suberanilohydroxamic acid and trichostatin [two histone deacetylase inhibitors (HDACIs)] and trifluoperazine and thioridazine (two phenothiazine-class drugs). Western blot analysis demonstrated that all four drugs had ETV1-downregulating effects. As HDACIs have been previously studied in GISTS, we focused on phenothiazine. Phenothiazine was found to exert cytotoxicity and to induce apoptosis and autophagy in GISTS. Treatment with phenothiazine had little effect on the KIT/AKT/mammalian target of rapamycin (mTOR) pathway, but instead upregulated the ERK/ELK1/EGR1 pathway, resulting in diminished autophagy, as well as enhanced apoptosis. On the whole, the findings of this study established phenothiazine as a novel class of therapeutic agents in GIST treatment and demonstrate that a combination of phenothiazine and MEK inhibitor has great potential for use in the treatment of GISTS.

Introduction

Gastrointestinal stromal tumors (GISTS) are the most common mesenchymal tumors of the gastrointestinal tract, occurring most frequently in the stomach (approximately 50%) and small intestine (25-35%) and less frequently in the colorectal regions (10-12%), omentum/mesentery (7%) and esophagus (1-5%) (1-3). The majority of GISTs contain mutations in the gene encoding the KIT tyrosine kinase receptor (4); however, but <10% have mutations in the gene encoding platelet-derived growth factor receptor A (PDGFRA) as the oncogenic driving force(5). Imatinib mesylate (Novartis Pharmaceuticals), a potent tyrosine kinase inhibitor (TKI) for both KIT and PDGFRα, is the standard first-line therapy and can achieve a median overall survival (OS) rate of 5-6 years in patients with advanced disease (6,7). However, disease progression, which most likely occurs due to the development of secondary mutations (8,9), is expected within 2 to 3 years of imatinib therapy (6,7). Therapeutic options are limited for these patients, with sunitinib maleate (Pfizer) as the standard second-line agent (10), and regorafenib (Bayer Schering Pharma AG) as third-line therapy (11,12).

KIT and its downstream pathway remain a major target of interest in TKI-refractory GISTS. Therapeutic strategies, such as those involving the degradation of the KIT protein [by using either a heat shock protein 90 inhibitor (13) or histone deacetylase inhibitors (14)] or the targeting of its downstream effectors by blocking phosphoinositide 3-kinase (15) or mammalian target of rapamycin (mTOR) (16), have been shown to be effective in inhibiting GIST growth. However,
only a few of these have been successfully applied in clinical studies (17-19). Consequently, identifying novel therapeutic targets or strategies against GIST is a priority.

By using bioinformatics analysis, Chi et al. discovered that ETS family member E26 variant 1 (ETV1) is highly expressed in GISTS (20). They also demonstrated that interstitial cell of Cajal (ICC) hyperplasia in mouse models expressing constitutively activated KIT also strongly expressed ETV1. Their analysis revealed that genes that were downregulated by ETV1 knockdown demonstrated a negative correlation with genes that were upregulated in GISTS, suggesting a key role of ETV1 in an ICC-GIST-specific transcription network. Furthermore, their study demonstrated that the ETV1 transcriptional program is further regulated by activated KIT and its downstream MAP kinase, which prolongs ETV1 protein stability and cooperates with ETV1 to promote tumorigenesis (20).

In their subsequent study, Ran et al. uncovered a positive feedback circuit in which the KIT/MAP kinase pathway stabilized the ETV1 protein and ETV1 positively regulated KIT expression. The combined targeting of ETV1 stability by using imatinib and MEK162 resulted in significant in vitro and in vivo cytotoxic effects (21). This series of studies demonstrated that ETV1 is a lineage-specific oncogenic transcription factor required for the growth and survival of GISTS, and that the identification of novel agents that target the ETV1 pathway may be a strategy for the treatment of GISTS.

Lamb et al. created a reference collection of gene expression profiles from cultured human cells treated with diverse bioactive small molecules, as well as pattern-matching software for data mining ['The Connectivity Map' (CMAP), http://www.broad.mit.edu/cmap/] (22,23). When any gene expression profiles of interest are uploaded to this database, pattern-matching algorithms score each reference profile for the direction and strength of enrichment with the query signature. Perturbagens are then ranked by this 'connectivity score'; those at the top ('positive') and bottom ('negative') are functionally connected with the query state through the transitory feature of common gene-expression changes (22). In this study, an ETV1 knockout gene signature of GIST cell lines was uploaded, and phenothiazine was identified as a class of ETV1-targeting agent in GISTS.

Materials and methods

Collection of expression profiles from public datasets. Microarray and clinicopathological data from the Gene Expression Omnibus (GEO) datasets GSE14827 [osteosarcoma (OS)], GSE13433 [alveolar soft part sarcoma (ASPS)], GSE8167 (GIST), GSE20196 [synovial sarcoma (SynSA)], GSE20559 [liposarcoma (LPS)] and GSE17679 [Ewing sarcoma family tumors (ESFT)] were obtained from the NCBI website. E-MEXP-1922 [leiomyosarcoma (LMS)] data were obtained from the ArrayExpress website. All datasets were in the Affymetrix U133 Plus 2.0 platform. In order to reduce intra-subtype heterogeneity, we did not include all samples. For OS, only tumors without subsequent metastasis were selected; for GISTS, only those with exon 11 mutations were included; for SynSA, only tumors with SYT-SSX type 1 fusion gene and non-poorly differentiated histology were analyzed; and for LPS, only well- and de-differentiated tumors were chosen due to their similar genetic background. Expression profile data of GIST cell lines with ETV1 wild-type versus knockout were also obtained from GEO (GSE19396) (20).

Bioinformatics analysis. dChip (24,25) was the main analytic software used, and the normalization of the expression values of individual chips was performed according to software specifications. One-way analysis of variance (ANOVA) was used to identify genes showing differentiated expression between different sarcoma subtypes, as well as different mutation status categories in GISTS. The expression levels of individual genes were obtained using z-score transformation, and the differences between different subtypes were then compared using the t-test.

Chip data from GSE19396 were analyzed separately. The dChip ‘Compare Samples’ function was used to explore differentially expressed genes between wild-type and ETV1 knockdown strains of GIST cell lines using 1.4-fold changes (with P<0.05 by the unpaired t-test) as the threshold (24) (please also refer to https://sites.google.com/site/dchipsoft/high-level-analysis/compare-samples/comparison-criteria).

Gene signature query of CMAP. The identified gene signature was first transformed to probe set ID of Human Genome U133A. Up- and downregulated ID lists were then uploaded to the CMAP website (http://www.broad.mit.edu/cmap/). The query signature was then compared with each rank-ordered list to determine whether upregulated query genes tend to appear near the top of the list and downregulated query genes near the bottom ('positive connectivity'), or vice versa ('negative connectivity'), yielding a ‘connectivity score’ ranging from +1 to -1. A null (zero) connectivity score was assigned where the enrichment scores for the up- and downregulated genes had the same sign. All instances in the database were then ranked according to their connectivity scores; those at the top were most strongly associated with the query signature, and those at the bottom were most strongly anti-associated (22,23).

Cell lines and mass ARRAY-based mutation characterization. GIST cell lines were kindly provided by Dr J.A. Fletcher, and the KIT mutation status of this line has been previously described (13). GIST882 is a human cell line established from an untreated GIST with a primary imatinib-sensitive homozygous missense mutation in KIT exon 13, encoding a K642E mutant KIT oncoprotein (26). GIST48 was established from GISTs that had progressed, after initial clinical response, during imatinib therapy. GIST48 has a primary, homozygous exon 11 missense mutation (V560D) and a heterozygous secondary exon 17 (kinase activation loop) mutation (D820A) (13).

The sequences of KIT of both cell lines were surveyed again by Mass ARRAY-based mutation characterization before this study. The Sequenom MassARRAY platform utilizes a homogeneous reaction format with a single extension primer to generate allele-specific products with distinct masses (27,28). PCR and extension primers for the mutations were designed using MassArray Assay Design 3.1 software (Sequenom). The mutation alleles were manually designed by extension in either the forward or reverse direction to have lower mass than the reference allele. The PCR products of multiplexed reactions were spotted onto SpectroCHIP II arrays, and DNA fragments were resolved by on the MassARRAY Analyzer 4.
Protein Assay kit (Thermo Fisher Scientific). Protein extracts by centrifugation for 30 min at 13,200 rpm at 4°C. Protein Lysates were incubated for 30 min at 4°C and then clarified. Inhibitor Cocktail (1:100 dilution; Thermo Fisher Scientific) containing the Protease and Phosphatase Inhibitor Cocktail (1:100 dilution; Thermo Fisher Scientific) was added and mixed thoroughly to dissolve the dark blue crystals. The absorbance of the converted dye was measured spectrophotometrically in a Vmax microplate reader (Molecular Devices) at wavelengths of 570 nm (test) and 650 nm. Cell viability was calculated as the percentage of MTT inhibition as measured through a FACSCalibur from BD Biosciences using CellQuest software.

**Western blot analysis.** Monolayers of cultured cells were rinsed in phosphate-buffered saline (PBS) and scraped into lysis buffer [25 nM Tris·HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS (Thermo Fisher Scientific)] containing the Protease and Phosphatase Inhibitor Cocktail (1:100 dilution; Thermo Fisher Scientific). Lysates were incubated for 30 min at 4°C and then clarified by centrifugation for 30 min at 13,200 rpm at 4°C. Protein concentrations were determined with the Pierce BCA Protein Assay kit (Thermo Fisher Scientific). Protein extracts (20-50 µg per lane) were electrophoretically separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels (8-12% depending on the molecular weights of proteins), transferred to polyvinylidene difluoride membranes (PerkinElmer), and blotted with specific antibodies. For primary antibodies, the sample was incubated at 4°C overnight; for secondary antibody, the sample was incubated at room temperature for 1 h. Immunoactive bands were detected using enhanced chemiluminescence (Millipore) and X-ray film.

**Measurement of caspase activity.** Caspase activity was measured using the Caspase-Glo® 3/7 assay kit (Promega) according to the manufacturer's instructions. Briefly, GIST cells (10^5 cells/well) were seeded in a luminometer plate and incubated for 24 h at 37°C. GIST cells were treated with DMSO (control vehicle) or with various concentrations of drugs for 72 h. Moreover, 100 µl of caspase-3/7 reagents was added to each well and mixed gently using a plate shaker. The cells were then incubated for 0.5-1 h at room temperature, and the luminescence of each well was measured.

**Apoptosis assessment by Annexin V staining.** The cells were plated at a density of 350,000 cells/well or 1,000,000 cells/well in 6-well plates. The following day, the cells were treated with TFP (0, 30 and 40 µM) or TDZ (0, 25 and 35 µM) for 72 h, and then washed with 1X PBS for twice and resuspended in 100 µl staining solution containing Annexin V-APC (BD Pharmingen) and propidium iodide in Annexin V-binding buffer. The cells were then incubated at room temperature for 15 min, and the cells were then diluted in 400 µl 1X Annexin V-binding buffer. The percentages of apoptotic cells were then measured using a flow cytometer (Canto II; BD Biosciences).

**Detection and quantification of autophagic cells by staining with acridine orange.** Cells were seeded in 6-well tissue culture dishes and treated with TFP (GIST882, 20 µM; GIST48, 10 µM) for 72 h. Moreover, 100 µl of caspase-3/7 reagents was added to each well and mixed gently using a plate shaker. The cells were then incubated for 0.5-1 h at room temperature, and the luminescence of each well was measured.
Results

Confirmation of the overexpression of ETV1 in GIST in comparison with other sarcomas. Eight different types of sarcoma were analyzed: GIST, OS, ASPS, SynSA, well-differentiated LPS (WD LPS), de-differentiated LPS (DD LPS), ESFT and LMS. Comparisons of the expression levels of three well-known GIST-specific expression genes, namely KIT, DOG1, and PRKCQ and ETV1, were made. As shown in Fig. 1, KIT, DOG1, PRKCQ and ETV1 were all significantly highly expressed in the GISTs in comparison with the other sarcomas.

Identification of novel agents targeting the ETV1 pathway in GIST by CMAP. We downloaded the expression profile information from the GEO database (GSE19396) created by Chi et al (20) and compared the expression profiles of wild-type GISTs and ETV1-knockdown GISTs. We obtained a total of 207 probes of genes with differential expression between these two types of cell lines (Tables SI and SII). We then uploaded this set of genes onto CMAP to search for possible agents. The five drugs that had the most significant P-values following permutation are presented in Table I. Prestwick-1080 is unavailable. SAHA and trichostatin are HDACIs, of which anti-GIST activity has been previously demonstrated (14). However, TFP and TDZ, two drugs of the phenothiazine class, have not been reported to date to have cytotoxic activity against GISTs, at least to the best of our knowledge. Therefore, we focused on these two drugs in this study.

Confirmation of the targeting of SAHA, TFP and TDZ on KIT-ETV1 in GIST cell lines. Subsequently, we examined
the targeting effect of TFP and TDZ, as well as other agents, on the KIT/ETV1 pathway. Representative western blots of GISTS882 and GIST48 following treatment with different agents are shown in Fig. 2. The inhibition of KIT signaling by imatinib (2 µM, 12 h) in the imatinib-sensitive GIST882 cells resulted in MEK pathway inhibition, as well as in ETV1 protein downregulation. The imatinib-resistant GIST48 cells exhibited changes to relevant pathways following treatment with imatinib at a higher concentration (20 µM, 12 h). By contrast, both GIST cell lines treated with the MEK inhibitor, PD98059 (100 nM, 12 h), exhibited an inhibition of ERK phosphorylation and the loss of ETV1. Previous research has demonstrated that KIT activity and expression, and the activation of downstream pathways in GISTS are strongly inhibited by HDACI (14). In this study, we also found that SAHA (10 µM, 12 h), an HDACI, degraded KIT, resulting in a subsequent decrease in ETV1 expression (Fig. 2).

We then further explored the targeting effects of TFP (35 µM, 72 h for GIST882; 25 µM, 72 h for GIST48) and TDZ (20 µM, 72 h for GIST882; 12.5 µM, 72 h for GIST48) on GIST cell lines. As shown in Fig. 2, ETV1 in the GIST882 and GIST48 cells was downregulated by TFP and TDZ. However, the expression levels of both total and activated KIT were not markedly affected by these two drugs. This result confirms that both TFP and TDZ have distinct targeting effects on the ETV1 pathway, compared with other drugs.

Both TFP and TDZ exert cytotoxic effects against GISTS. We then evaluated the cytotoxic effects of TFP on GIST cell lines. As shown in Fig. 3A and B, both TFP and TDZ exerted significant anti-proliferative effects on the GIST48 and GIST882 cells in a dose-dependent manner. However, TFP induced caspase activation in the GIST48 cells, but not in the GIST882 cells (Fig. 3C and D). A significant increase in the number of apoptotic cells, as assessed by Annexin V staining, was easily observed in the GIST48 cells treated with both agents. However, this could only be seen in the GIST882 cells at relatively higher concentrations of phenothiazine-class drugs (Fig. 3E and F). These results indicate that both TFP and TDZ exert a cytotoxic effect against GISTS, but not always through apoptosis.

**TFP and TZD induce autophagy and the downregulation of ETV1 with the paradoxical upregulation of ERK in GIST cell lines.** Phenothiazine drugs are a well-known class of drugs that induce autophagy (31). In this study, we evaluated the possibility of autophagy induction in GIST cells following drug treatment. As illustrated in Fig. 4, both TFP and TDZ induced autophagy in GISTS, as demonstrated by an increased LC3-II expression. Quantitative fluorescence-activated cell sorting (FACS) analysis revealed an increase in lysosomes following drug treatment (Fig. 5). These results indicate that TFP and TDZ can induce autophagy in GIST cell lines. PARP cleavage, an indicator of apoptosis, was also observed in the GIST48 and, to a lesser extent, in the GIST882 cells. This is compatible with the distinct pattern of caspase activation observed in both cell lines following treatment with TFP.

Chi et al revealed that ETV1 was a downstream effector of MEK and that MEK inhibition causes ETV1 downregulation (20). Similar findings were also noted in this study (Fig. 2). However, the GIST cell lines treated with TFP or TDZ exhibited an ETV1 downregulation with a paradoxical ERK activation (Fig. 4), indicating a MEK-independent mechanism in ETV1 degradation. TFP induced the suppression of the AKT (indicated by p-AKT)/mTOR (indicated by p-p70s6k) signaling pathway in the GIST48 cells at a relatively high concentration (25 µM). In addition, the downregulation of p-KTI was observed in the TFP-treated GIST48 (20 and 25 µM) and GIST882 (35 µM) cells. No marked changes in the KIT/AKT/mTOR signaling were observed in the TDZ-treated GIST cells.
TFP or TDZ act synergistically with the MEK inhibitor, MEK162, to exert a cytotoxic effect on GIST cell lines and the combination of phenothiazine with MEK162 induces apoptosis with diminished autophagy and the downregulation of ERK and downstream ELK1 and EGR1. As we observed paradoxical ERK activation following phenothiazine treatment, we then evaluated the possibility of combining phenothiazine with an MEK inhibitor to treat GISTs. As shown in Fig. 6, TFP or TDZ acted synergistically with the MEK inhibitor, MEK162, in inducing cytotoxic effects in the GIST48 and GIST882 cells.

The mechanisms of autophagy induction by phenothiazine are unclear. EGR1 is a member of the EGR family of C2H2-type zinc finger proteins. It is a nuclear protein and functions as a transcriptional regulator, and it is also known to be responsible for environmental stress-induced autophagy, such as that caused by smoking (32). Additionally, EGR1 expression can be induced by ELK1, which is a member of the Ets family of transcription factors and of the ternary complex factor (TCF) subfamily, as well as a known nuclear target for the RAS/RAF/MAPK signaling cascade (33). Consequently, we considered that phenothiazine-induced autophagy may occur through ERK activation of the ELK1/EGR1 pathway. As shown in Fig. 7, TFP or TDZ induced autophagy with concomitant ERK, ELK1 and EGR1 activation. However, the combination of MEK162 and phenothiazine downregulated ERK, and downstream ELK1 and EGR1 with a resultant decrease in autophagy. Apoptosis, based on PARP cleavage, seemed more apparent in cells treated with the MEK162 and TFP combination. This result indicates that phenothiazine-induced autophagy may occur through the ERK/ELK1/EGR1 pathway, and the combination of phenothiazine with MEK inhibitor is a potential strategy for the treatment of GISTs.

Discussion

In this study, by uploading the differential expression gene sets of wild-type versus knockdown ETV1 to CMAP, we identified several agents with therapeutic potential. Among these, phenothiazine had not been reported previously, at least to the best of our knowledge. Phenothiazine-derived drugs were found to
exert cytotoxicity and could induce apoptosis and autophagy in GISTs. Phenothiazine had little effect on the KIT/AKT/mTOR pathway, but instead paradoxically upregulated ERK activity. Phenothiazine may induce autophagy through the activation of the MEK/ERK/ELK1/EGR1 pathway, and the combination of phenothiazine and a MEK inhibitor had a synergistic cytotoxic effect on GISTs.

The important role of ETV1 in GIST was first revealed by Chi et al (20). Their study demonstrated that ETV1 was regulated by the KIT/MAP kinase pathway, and plays a key role in...
an ICC-GIST-specific transcription network (20). Furthermore, a
positive feedback circuit between the KIT/MAP kinase pathway
and ETV1 was found, and a combination therapy of imatinib and
MEK162 to target ETV1 stability resulted in considerable tumor
suppressive effects (21). Their studies led us to explore the agents
with ETV1-targeting potentials in GIST treatment.

In this study, through the analysis of a public-domain
database, we found that ETV1, along with several known
Figure 6. Viability of GIST48 and GIST882 cells following treatment with various concentrations of TDZ, TFP, or MEK162 alone, or a combination of
phenothiazine with MEK162, was measured with the TACS™ MTT cell proliferation assay (expressed as a percentage of viability under controlled culture
conditions). A significant synergistic effect of combination of phenothiazine with MEK162 could be observed in both GIST cell lines at all levels of concentra-
tion [*; combination index (CI) <1]. TFP, trifluoperazine; TDZ, thioridazine.

Figure 7. Western blot analysis of (A) GIST882 and (B) GIST48 cells following treatment with either TFP or TDZ, or in combination with MEK162. Increased
LC3-II expression was found following TFP and TDZ treatment with concomitant activation of ERK, ELK1 and EGR1. Combination of MEK162 and phenothiazine diminished autophagy, enhanced apoptosis, and downregulate ERK and downstream ELK1 and EGR1.
genes such as KIT, DOG1, and PKC0, was significantly overexpressed in GISTs in comparison with other sarcomas. This is consistent with previous reports (20,34), again demonstrating the uniqueness and importance of ETV1 in GISTs. Subsequently, we uploaded an ETV1 knockout gene signature of GIST cell lines to CMAP, and we identified several ETV1 targeting agents. CMAP is a genome-wide transcriptional expression database generated from cultured human cells treated with bioactive small molecules. It applies a simple pattern-matching algorithm to discover the functional connections between drugs, genes, and diseases through common gene-expression changes. This database has been widely used in the discovery of novel agents and in deciphering previously unknown molecular mechanisms (35-38). In this study, through CMAP analysis of an ETV1 knockout gene signature of GIST cell lines, we discovered SAHA and trichostatin (two HDACIs) and TFP and TDZ (two drugs of phenothiazine class) as ETV1-targeting agents.

As expected, HDACIs were on the list, as a previous study has already shown their activity in downregulating KIT (14). In this study, we also demonstrated their activity by western blot analysis (Fig. 2). However, phenothiazine has not been previously reported to have anti-GIST activity, at least to the best of our knowledge. Phenothiazine has been identified as a class of potential anticancer drugs in previous publications. Possible mechanisms include inhibiting the PDK1/AKT pathway (39,40), Wnt/b-catenin pathway (41), dopamine receptors (42), HSP70 (43) and DNA repair (44). In this study, we did not observe a significant effect of phenothiazine on receptors (42), HSP70 (43) and DNA repair (44). In this study, we did not observe a significant effect of phenothiazine on the KIT/AKT/mTOR pathway. However, paradoxical ERK activation was found following treatment with the drugs.

The mechanisms of paradoxical ERK activation following phenothiazine or MEK162 treatment are not clear. ERK pathway activity is regulated by negative feedback at multiple levels, including the transcriptional activation of DUSP proteins that negatively regulate the pathway. ERK also phosphorylates and thus regulates upstream CRAF, SOS and MEK activity directly (45). One possible hypothesis is that these feedback inhibitory pathways may be temporarily shut down after phenothiazine- or MEK162- induced ERK inhibition, with resultant re-activation of ERK, and complete inhibition could only be achieved by combination of different agents targeting different levels. However, the specific underlying mechanisms warrant further investigation.

Although phenothiazine has been demonstrated to be a class of autophagy-inducing agents (31), the associated mechanism is still unclear. Chen et al discovered the role of EGR1 in autophagy by showing that cigarette smoke extract (CSE) could reduce HDAC activity, which resulted in increased binding of EGR1 and EZF factors to the LC3B promoter with subsequently increased LC3B expression in human pulmonary epithelial cells (32). Additionally, Guha et al revealed that lipopolysaccharides induced ELK1 phosphorylation through the MEK/ERK1/2 pathway with the subsequent induction of EGR1 expression in monocytes (33). As we observed ERK activation following phenothiazine treatment, we then explored the role of ERK activation in autophagy. In this study, we revealed that a combination of phenothiazine and a MEK inhibitor had a synergistic cytotoxic effect on GISTs. Western blot analysis indicated that MEK inhibition diminished autophagy and, together with phenothiazine, induced apoptosis. We also demonstrated that both ELK1 and EGR1 were activated/upregulated following TDZ and TFP treatment, but both were downregulated with a concomitant decrease in LC3-II expression after MEK inhibition. This result indicates that phenothiazine-induced autophagy may be mediated through the MEK/ERK/ELK1/EGR1 pathway and that the combination of phenothiazine with a MEK inhibitor may be a potential strategy for the treatment of GISTs.

In conclusion, in this study, by using bioinformatics analysis through CMAP, we identified TFP and TDZ, two drugs of phenothiazine class, as potential ETV1-targeting agents in GIST treatment. Phenothiazine-derived drugs induced apoptosis and autophagy in GISTs. Phenothiazine treatment was found to paradoxically upregulate ERK activity, but with little effect on the KIT/AKT/mTOR pathway. Phenothiazine may induce autophagy in GISTs through the MEK/ERK/ELK1/EGR1 pathway. A combination of phenothiazine and a MEK inhibitor exerted a synergistic cytotoxic effect on GISTs. Additional in vivo or clinical studies are warranted for further confirmation.

Acknowledgements

This manuscript was edited by Wallace Academic Editing.

Funding

This study was jointly supported by the grants from the Department of Health in Taiwan (Center of Excellence for Cancer Research at Taipei Veterans General Hospital, grant nos. DOH99-TD-C-111-007 and DOH100-TD-C-111-007, and the National Research Program for Biopharmaceuticals, grant no. DOH100-TD-PB-111-TM026), National Science Council (NSC 100-2314-B-075-081 and NSC 101-2314-B-075-079), Ministry of Science and Technology, Taiwan, (MOST 103-2314-B-075-066, MOST 105-2314-B-075-059, MOST 106-2314-B-075-065), Taipei Veterans General Hospital (V102E8-003, V103E8-001, V101C-133, V102C-034, V103C-188, V104C-099, V104E16-001-MY3-1, V104E16-001-MY3-2, V104D16-001-MY3-3, V105C-094, V106C-160, V107C-085, V107D32-001-MY2-2, V108C-108) and from the Yen Tjing Ling Medical Foundation (grant no. CI-100-19, CI-103-6, CI-105-4) designated to CCY. This study was also supported by the Taiwan Clinical Oncology Research Foundation, and Chong Hin Loon Memorial Cancer and Biotherapy Research Center of National Yang-Ming University.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

JAF, CCY, LTC and CFL were responsible for the design and conception of the study; WYC, YCL, CHY and YCC were responsible for data acquisition and interpretation; SCC, MHY and YC were responsible for the data analysis and drafting.
the work. All of the authors have read and approved the final manuscript for publication.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


